FDA OK’s IL-17As for nr-axSpA, But Few See Changes Ahead With Chart: Current Market Access to Ankylosing Spondylitis Medications
June
25
The FDA’s approvals of two interleukin-17A (IL-17A) antagonists to treat active non-radiographic axial spondyloarthritis (nr-axSpA) give providers new options for patients who are intolerant of non-steroidal anti-inflammatory medications (NSAIDs) and other therapies.
But the FDA’s decision to greenlight Eli Lilly and Co.’s Taltz (ixekizumab) and Novartis Pharmaceuticals Corp.’s Cosentyx (secukinumab) for the condition are unlikely to shake up plan formularies, since IL-17As currently are considered third-line treatments for the condition, PBM insiders say.
© 2025 MMIT
Meet Our Reporters
-
Jill Drachenberg Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jill Drachenberg's Profile -
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
